Skip to main content

Mate Whenua-Follow-Up After Early Medical Abortion in New Zealand: A Randomised Controlled Trial

Journal
BJOG : an international journal of obstetrics and gynaecology (Q1)
Published
25 October 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Wise MR, Knowles A, Talbot S, Parag V, Lawton B, Edmonds M, et al.
PMID
42928632
DOI
10.1111/1471-0528.70346

Why clinicians should know about it

  • Picked for Obstetrics and Gynecology (top studies of the week, 22 November 2026): Self-assessment improves follow-up after early medical abortion

Abstract

OBJECTIVE: To evaluate self-assessment with low sensitivity urine pregnancy test versus comparative serum bhCG in women having early medical abortion (EMA) for the outcomes of complete follow-up and ongoing live pregnancy. DESIGN: Multi-centre parallel group randomised controlled trial. SETTING: Six abortion services in Aotearoa New Zealand. POPULATION: Pregnant women having EMA. METHODS: Participants were randomised on a 1:1 ratio, stratified by centre, to a follow up protocol, self-assessment, or blood tests. Chi-squared tests, relative risks, and absolute risk differences (with 95% confidence intervals) were calculated. MAIN OUTCOME MEASURES: Primary outcome was complete follow-up (able to discuss follow-up test result within 6 weeks). Secondary outcomes were successful abortion; contraception; complications; and additional services. RESULTS: There were 732 participants. More participants in the self-assessment group had complete follow-up compared to the blood test group (94.5% vs. 67.4%, p < 0.001; relative risk (RR) 1.41 [95% confidence interval (CI) 1.30-1.52]). More participants in the self-assessment group had a successful EMA (89.0% vs. 81.0%, p = 0.002; RR 1.10 [95% CI: 1.03-1.17]) and more additional follow up investigations (17.3% vs. 11.1%, p = 0.017; RR 1.55 [95% CI: 1.08-2.24]). There were no differences between groups in contraception (61.0% vs. 56.0%; RR 1.09 [95% CI: 0.96-1.23]), additional health care visits (11.% vs. 10.3%; RR 1.06 [95% CI: 0.70-1.62]), community prescriptions (4.4% vs. 5.2%; RR 0.85 [95% CI: 0.44-1.63]) or complications (8.5% vs. 8.7%; RR 1.09 [95% CI: 0.96-1.23]). There was one ongoing live pregnancy detected after the first trimester. CONCLUSIONS: The authors recommend self-assessment after EMA for improved follow-up. In addition to demonstrating clinical effectiveness and safety, the findings have important implications for improving reproductive health equity. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12623000890639 (registered prospectively on 21/08/2023; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384373&isClinicalTrial=False).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.